AstraZeneca PLC on Friday announced plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland.
The Cambridge, England-based pharmaceuticals company said this includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials.
Friday’s announcement is part of AstraZeneca‘s $50 billion investment announced in July and follows a series of US commitments over the past six months, including unveiling a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of the Company’s existing manufacturing facility in Coppell, Texas.
Shares in AstraZeneca closed up 0.6% at 13,734.00 pence each in London on Friday.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
